Nanosynth group positioned to move ahead positively

nanosynth group plc (LON:NNN), the AIM quoted company has presented its unaudited half yearly report for the six-month period ended 30 June 2021.

OVERVIEW

· The financial commentary is set out below and the following events have all occurred post 30 June 2021.

o  On 17 August 2021, the Company agreed to return control of Gyrometric Systems Ltd to its founders, leaving the Company with a minority holding of 15%.

o  On 23 August 2021, Remote Monitored Systems plc changed its name to nanosynth group plc following shareholder approval at its Annual General Meeting

o  On 24 August 2021, the Company agreed to return the mask making machine to Lemu Group for a minimum of €180,000

o    On 1 September 2021, Mark Duffin was appointed Chief Executive Officer of nanosynth group plc and Antony Legge reverted to his previous role of non-executive Chairman.

CHAIRMAN’S STATEMENT

The arrival of Mark Duffin as Group CEO on 1 September 2021, has brought a new dynamism to the business.  As previously announced, the year to date has posed several challenges as the Company has needed to undertake a number of significant changes.  The restructuring of the Group is now nearly completed. The mask manufacturing machine will now be returned to Lemu Group within the next month with cash receipts to follow accordingly, and the manufacturing of the masks is now fully outsourced, leaving the Group free to concentrate on the development of the intellectual property that exists inside Pharm 2 Farm Ltd (“P2F”), the Group’s main subsidiary.  At the time of the Annual General Meeting, just six weeks ago, we announced that discussions were ongoing regarding several initiatives and we remain confident that these will be concluded satisfactorily in the near term.  Sales remains a key focus and the team here is being strengthened with new sales and marketing hires. 

There still remains work to be done, but I am confident that after all the developments in the year to date, the Group is positioned to move ahead positively.

Mark Duffin, nanosynth CEO, commented:

“Since my arrival four weeks ago, it is clear that there is an opportunity within the Group to develop and productise a host of future R&D streams of activity. The depth of scientific knowledge is encouraging and this will support the commercialisation of future products. Notwithstanding this, changes need to be made so that the Group can develop the market opportunities.  Significant progress has been made in a short space of time and we’re looking forward to the future.”

Financial Overview 

During the six months to 30 June 2021, the Group recorded revenues from continuing operations of £135,116 compared with £13,563 for the six months to 30 June 2020.  The operating loss from continuing operations for the periodwas £1,194,493 (30 June 2020: £199,740).  This includes the previously announced payments to FortOak Rolls Limited (a company wholly owned by Alex Vergopoulos, a former director of the Company) of 150,000 and 8 million shares and options over a further 7 million shares in recognition of services provided. The loss for the periodfrom continuing operations was £1,194,493 (30 June 2020: £202,862). The loss per share was 0.058 pence (30 June 2020: loss per share 0.041 pence).

● Consolidated net assets at 30 June 2021 amounted to £6,943,250 (31 December 2020: £6,896,805).

● Cash and cash equivalent balances at the period end amounted to £4,665,424 (31 December 2020: £3,741,135).

● As at 29 September 2021, the Group had cash and cash equivalents totalling £4,140,540.

● During the period the Company raised £939,225 net of costs through the issue of new shares as a result of the exercise of warrants and options. In addition £1,505,000 was received in respect of shares issued in the previous period.

Acknowledgments

On behalf of the Board, I would like to extend our thanks to our business partners, customers, employees and shareholders for their continued support throughout the period. 

Antony Legge

Non-Executive Chairman

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Nanosynth Group plc

    More articles like this

    Nanosynth Group plc

    Nanotechnology in cosmetics and cosmeceuticals

    Nanoparticles (NPs) are defined as materials with dimensions smaller than 100 nm and presenting various shapes, i.e., spheres, rods, dendritic shapes, etc. This definition is accepted by the European Union (EU) Commission. It should be noted, however,

    Nanosynth Group plc

    Nanoparticles in cosmetics

    Nanoparticles are particles that are smaller than 100 nanometer (1/10,000 millimeter) which is about 40,000 times thinner than a hair. There are two forms of nanoparticles: soluble and biodegradable nanoemulsions such as liposomes and insoluble nanopigments

    Nanosynth Group plc

    What nanoparticles do to our cells

    During the past few years, nanoparticles have been increasingly present in our everyday lives. To gain a better understanding of their health impacts, several studies have focused on the effects they have on our bodies and

    Nanosynth Group plc

    Role of nanotechnology for design and development of cosmeceutical

    Nanotechnology is an innovative area of science that includes the design, characterization, production, and application of materials, devices and systems by controlling shape and size at the nanometer scale (1–100 nm). Nanotechnology incorporation in cosmetic formulation

    Nanosynth Group plc

    Nanotech could be the next frontier of drug delivery

    Nanotechnology is an emerging and rapidly developing area in the pharmaceutical and medicinal field. For example, nanoparticles can be used as drug delivery systems. Nanotechnology could help overcome the limitations of conventional drug delivery such as biodistribution and

    Nanosynth Group plc

    Nanoparticles to aid cancer treatments

    Conventional therapies in cancer treatment face challenges in delivery of drugs in the body and just the quantity needed, due to the toxic nature of the medicines used that have unwanted side effects. Nanomaterials have ‘enormous’

    Nanosynth Group plc

    Nanoparticles: Emerging trends in human health and environment

    As part of the ongoing Govt of India initiative “Azadi ka Amrit Mahatosav”, the Indian Journal of Biochemistry and Biophysics (IJBB), CSIR-National Institute of Science Communication and Policy Research (NIScPR), New Delhi, has brought out its

    Nanosynth Group plc

    Nanoparticles that self-assemble inside cells to fight cancer

    Inspired by viral replication, researchers developed a therapy that commandeers biological processes to craft nanoparticles within macrophages to aid in cancer therapy. Through self-assembly, the nanoparticles address some of the delivery issues plaguing present renditions of nanomedicines,

    Nanosynth Group plc

    nanosynth Group getting a huge amount of traction (LON:NNN)

    nanosynth’s Mark Duffin discusses what the company does, the Volz trial results, joint venture with a global wellness company and what investors can expect for the rest of the year in this exclusive interview with DirectorsTalk.

    Nanosynth Group plc

    Nanotechnology in the nutricosmetics industry

    Nanotechnology for Nutricosmetics Nanocarriers are ubiquitous within nanomedicine; however, with skin quality and health in high demand for consumers, these fields have overlapped. The use of nanotechnology and nanoformulations as delivery systems for improving the performance

    Nanosynth Group plc

    Nanotechnology in cosmetics

    Nanotechnology is the science of manipulating atoms and molecules in the nanoscale – 80,000 times smaller than the width of a human hair. The world market for products that contain nanomaterials is expected to reach $2.6